Extraglandular Manifestations of Sjögren's Syndrome
Among the options listed, thrombocytopenia and bronchiectasis are recognized extraglandular manifestations of Sjögren's syndrome, while CML and ulcerative colitis are not established associations.
Recognized Extraglandular Manifestations
a) Thrombocytopenia - YES
Thrombocytopenia is a well-documented hematologic extraglandular manifestation of Sjögren's syndrome. The 2021 Chest consensus guidelines specifically list thrombocytopenia among the known risk factors for lymphoproliferative complications in Sjögren's patients 1. Multiple case reports confirm that immune-mediated cytopenias, including thrombocytopenia, can present as clinically significant extraglandular manifestations of primary Sjögren's syndrome 2, 3, 4.
- Clinical presentation: Can occur with or without sicca symptoms
- Mechanism: Immune-mediated platelet destruction
- Treatment response: Typically responds well to corticosteroid therapy 2
- Diagnostic consideration: Sjögren's syndrome should be actively sought in patients with apparently "idiopathic" thrombocytopenia through directed history, Schirmer test, and autoantibody screening 3
c) Bronchiectasis - YES
Bronchiectasis is a clearly established pulmonary manifestation of Sjögren's syndrome. The 2021 Chest consensus guidelines provide strong recommendations (LOW evidence, STRONG recommendation) for managing clinically relevant bronchiectasis in Sjögren's patients 1.
- Prevalence: Upper and lower airway disease is reported in association with Sjögren's 1
- Radiographic definition: Atypical dilation of airways larger than the accompanying bronchial artery, or visible to 1 cm of the costal pleural margin 1
- Clinical context: Part of the spectrum of pulmonary complications including xerotrachea, bronchiolitis, obstructive lung disease, and interstitial lung disease 5, 6
- Management: Treat similarly to primary or secondary bronchiectasis of other etiologies, including mucolytic agents, nebulized saline, airway clearance techniques, and chronic macrolides (in absence of non-tuberculous mycobacterium) 1
Non-Recognized Associations
b) CML (Chronic Myelogenous Leukemia) - NO
CML is not an established extraglandular manifestation of Sjögren's syndrome. While Sjögren's patients have increased risk for lymphoproliferative disorders (particularly B-cell lymphomas, especially MALT lymphoma), this represents lymphoid rather than myeloid malignancy 1. The lymphoma risk in Sjögren's ranges from 5-18%, but these are predominantly B-cell non-Hodgkin lymphomas, not myeloid leukemias.
d) Ulcerative Colitis - NO
Ulcerative colitis is not recognized as an extraglandular manifestation of Sjögren's syndrome. The provided evidence includes comprehensive reviews of extraglandular manifestations 5, 6, 7, 8, and none mention inflammatory bowel disease as an associated feature. The 2020 EULAR recommendations 9 and multiple systematic reviews of extraglandular manifestations do not list gastrointestinal inflammatory conditions like ulcerative colitis among the systemic features of Sjögren's syndrome.
Clinical Pearls
Common pitfall: Failing to recognize that Sjögren's syndrome can present with extraglandular manifestations (including thrombocytopenia or pulmonary disease) in the absence of sicca symptoms 3. Maintain high clinical suspicion and actively screen with autoantibodies (anti-SSA/Ro, anti-SSB/La), Schirmer test, and directed history when encountering unexplained cytopenias or pulmonary disease.
Answer: a) and c) are correct